Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Kallistatin Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Serpin A4, Kallikrein inhibitor, Peptidase inhibitor 4, PI-4, SERPINA4, KST, PI4, Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 4
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


Availability on Request RD191436200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Urine, Cerebrospinal fluid, Bronchoalveolar lavage, Amniotic fluid, Milk, Plasma (EDTA, citrate, heparin)

Sample Requirements

Serum, plasma, CSF, Amniotic fluid, and Breast milk: 5 µl/well
BALF and urine: 35 µl/well
The kit has to be customized to reach sensitivity needed for detection of kallistatin in urine.
Please contact us at info@biovendor.com for more information

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.25 – 16 ng/ml

Limit of Detection

109 pg/ml

Intra-assay (Within-Run)

n = 8; CV = 5.0 %

Inter-assay (Run-to-Run)

n = 6; CV = 5.7 %

Spiking Recovery

102.4 %

Dilution Linearity

98.2 %

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 3.5 hours
  • The kit measures kallistatin in serum, plasma (EDTA, citrate, heparin), cerebrospinal fluid (CSF), bronchoalveolar lavage fluid (BALF), breast milk and amniotic fluid
  • Urine samples can also be analyzed; however, the kit has to be customized to reach sensitivity needed for detection of kallistatin in urine. Please contact us at info@biovendor.com for more information
  • Assay format is 96 wells
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Cardiovascular disease, Diabetology - Other Relevant Products, Energy metabolism and body weight regulation, Immune Response, Infection and Inflammation, Oncology

Summary

Kallistatin (Kallikrein-Binding Protein – KBP, Serpin A4) is an acidic glycoprotein composed of 427 amino acids and molecular weight of 58 kDa. It belongs to the serine proteinase inhibitor (SERPIN) superfamily and is a specific endogenous inhibitor of tissue kallikrein. Tissue kallikreins are a group of serine proteinases which are best known for their ability to process plasma kininogens to generate kinins which cause vasodilation. The kallistatin protein contains two structural elements: an active site and a heparin-binding domain. The active site is crucial for complex formation with tissue kallikrein, and thus tissue kallikrein inhibition. The inhibitory activity of kallistatin is blocked upon its binding to heparin. The heparin binding domain, however, is essential for antagonizing signaling pathways mediated by vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF)-α, high mobility group box-1 (HMGB1), and transforming growth factor (TGF)-β. Kallistatin is synthesized and secreted by a wide range of human tissues including kidney, liver, eye, heart, prostate, colon, blood vessels and blood cells. Kallistatin has multiple biologic functions independent of the tissue kallikrein-kinin system and exhibits pleiotropic effects in vasodilation, inhibition of inflammation, angiogenesis, fibrosis, apoptosis, oxidative stress and cancer progression. In animal models, kallistatin administration by gene or protein delivery was observed to offer protection against a large number of pathological conditions such as hypertension, cardiovascular and organ damage, arthritis, sepsis, influenza virus infection, tumor growth and metastasis and has potential for use as a therapeutic agent or target. Kallistatin levels in circulation, body fluids or tissues are significantly lower in patients with liver disease, obesity, septic syndrome, severe pneumonia, inflammatory bowel disease, and cancer of the colon and prostate. Decreased kallistatin levels were observed in vitreous fluid of patients with diabetic retinopathy, however, circulating kallistatin serum levels were shown to be elevated in type 1 diabetes patients with vascular complications. Similar results were observed in type 2 diabetic patients in which serum kallistatin is also increased and correlates with the presence of retinopathy. A recent study demonstrated that serum kallistatin levels are significantly reduced in patients with liver cirrhosis (LC) but not in hepatocellular carcinoma and this decrease correlates with the degree of LC and disruption of normal liver function.

Summary References (12)

References to Kallistatin

  • Chao J, Bledsoe G, Chao L. Kallistatin: A novel biomarker for hypertension, organ injury and cancer. Austin Biomark & Diagn. 2015;2 (2)
  • Chen VC, Chao L, Pimenta DC, Bledsoe G, Juliano L, Chao J. Identification of a major heparin-binding site in kallistatin. J Biol Chem. 2001 Jan 12;276 (2):1276-84
  • Cheng Z, Lv Y, Pang S, Bai R, Wang M, Lin S, Xu T, Spalding D, Habib N, Xu R. Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharm Sin B. 2015 May;5 (3):194-200
  • Gao L, Li P, Zhang J, Hagiwara M, Shen B, Bledsoe G, Chang E, Chao L, Chao J. Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc. 2014 Oct;3 (5):e001194
  • Jenkins AJ, McBride JD, Januszewski AS, Karschimkus CS, Zhang B, O'Neal DN, Nelson CL, Chung JS, Harper CA, Lyons TJ, Ma JX. Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. J Angiogenes Res. 2010;2:19
  • Li P, Guo Y, Bledsoe G, Yang ZR, Fan H, Chao L, Chao J. Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit Care. 2015;19:200
  • Lin WC, Chen CW, Huang YW, Chao L, Chao J, Lin YS, Lin CF. Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep. 2015;5:12463
  • Liu X, Zhang B, McBride JD, Zhou K, Lee K, Zhou Y, Liu Z, Ma JX. Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway. Diabetes. 2013 Dec;62 (12):4228-38
  • Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 2002 Nov 1;100 (9):3245-52
  • Shen B, Hagiwara M, Yao YY, Chao L, Chao J. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 2008 May;51 (5):1358-65
  • Yin H, Gao L, Shen B, Chao L, Chao J. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension. 2010 Aug;56 (2):260-7
  • Zhou GX, Chao L, Chao J. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem. 1992 Dec 25;267 (36):25873-80
Related Products Docs